Rinvoq is granted reimb for ankylosing spondylitis
By Son, Hyung-Min | translator Kim, Jung-Ju
23.12.13 13:23:10
가나다라
0
AbbVie holds press conference in celebration of Rinvoq’s reimbursement approval in ankylosing spondylitis
Rinvoq is reimbursed for the treatment of adults with severe active ankylosing spondylitis on the 1
Unmet needs remain in ankylosing spondylitis…’ Rinvoq will be highly utilized in the field”
▲AbbVie Korea holds press conference in celebration of Rinvoq’s reimbursement approval in ankylosing spondylitis on the 13th
The use of JAK inhibitors, which had been used for rheumatoid arthritis and atopic dermatitis, has been expanded to ankylosing spondylitis. On the 13th, AbbVie Korea held a press conference at Andaz Seoul Gangnam in Gangnam-gu, Seoul to celebrate the reimbursement of its Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib) for severe active ankylosing spondylitis.
Rinvoq was granted reimbursement for the treatment of adults with severe active ankylosing spondylitis on the 1st. Rinvoq is reimbursed for use in patients with severe active ankylosing spondylitis who have had an inadequate response to or had to discontinue treatment with tumor necrosis factor-alpha (TNF-α) blockers or interl
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)